-
Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson’s Disease: Phase 2a Double-Blind, Randomized Controlled Trial
… neuroinflammation in PD. Hypothesis: We hypothesize that multiple intravenous infusions of mesenchymal stem cells … Next Steps for Development: This trial aims to prove that multiple infusions of mesenchymal stem cells are a safe and …
-
Research Perspective: Blood-Based Biomarkers in Parkinson’s
September 9, 2020
… categories for research. The authors asserted that a system of biomarkers, rather than one alone, was necessary … We suspect we will leverage a similar approach, using multiple biomarkers in combination. The elements of the …
-
Daniel Weintraub, MD
… complications of Parkinson’s disease. He serves on multiple task forces and working groups of the International …
-
Tomohiro Nakamura, PhD
… disorders, including Parkinson’s disease, and he has multiple publications in Science, Nature, and Cell Press on …
-
Jacob Hesterman, PhD
… information required to support projects spanning multiple imaging modalities and therapeutic areas. Prior to …
-
Isogenic human SNCA gene dosage induced pluripotent stem cells to model Parkinson's disease
March 1, 2022
… disease (PD). Clinical cases with alpha-synuclein (SNCA) multiplications or deletions indicate that gene expression …